Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Efavirenz + Emtricitabine + TDF bulk supplier for pharma manufacturers

Efavirenz + Emtricitabine + TDF 600/200/300 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 600/200/300 mg

Reference Brands: Atripla(US/EU)

Category: Anti Viral

Efavirenz 600 mg, emtricitabine 200 mg and tenofovir DF 300 mg tablets, a complete once-daily single-tablet HIV regimen. For national HIV programmes, donor-funded tenders, hospitals and licensed importers.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Efavirenz + Emtricitabine + TDF? List it or send an offer →

Product Description:

This single tablet holds a complete once-daily HIV regimen: efavirenz 600 mg, a non-nucleoside reverse transcriptase inhibitor, with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, two nucleoside or nucleotide reverse transcriptase inhibitors. The three drugs act on the same viral enzyme at two different sites, making resistance harder to develop. A close relative uses lamivudine in place of emtricitabine; they are not the same product, and tenders specify which they want.

WHO guidelines now prefer dolutegravir-based first-line treatment, with efavirenz kept as an alternative, often at 400 mg, so demand for this 600 mg form has fallen. It is taken once daily on an empty stomach, ideally at bedtime, to ease efavirenz's dizziness, vivid dreams and mood changes. A psychiatric history needs care. Tenofovir DF can harm kidney function and bone density, so creatinine is checked. Efavirenz induces liver enzymes, lowering levels of many drugs including some hormonal contraceptives. Stopping it in hepatitis B co-infection can trigger a flare.

Sourcing notes. Donor-funded and public tenders usually want WHO prequalification or stringent-authority approval; ask for the reference and check that it is current. Confirm patent and licensing status in the destination before quoting. Request a CoA per batch with assay, dissolution and related substances for all three actives, the bioequivalence report, the GMP certificate and a CoPP. The large film-coated tablets are moisture-sensitive and usually packed 30 to an HDPE bottle with desiccant. Zone IVb stability data matter for hot humid markets. State bottle count, quantity and label language.

Efavirenz + Emtricitabine + TDF — third party manufacturing & bulk supply

Efavirenz + Emtricitabine + TDF 600/200/300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Efavirenz + Emtricitabine + TDF is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Efavirenz + Emtricitabine + TDF listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Efavirenz + Emtricitabine + TDF →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Efavirenz, emtricitabine, and tenofovir disoproxil fumarate (TDF) are used together as a single-tablet regimen to treat HIV-1 infection. This combination helps lower viral load, improve immune function, and prevent HIV progression when taken regularly.

It is made from three antiretroviral agents: efavirenz (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (an NRTI), and tenofovir disoproxil fumarate (an NRTI). Together they block HIV replication at multiple stages.

The common trade name is Atripla.

Atripla is co-developed by Gilead Sciences and Bristol-Myers Squibb, with several generic manufacturers producing it globally.

The generic name is efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

The primary brand name is Atripla.

It is manufactured in approved facilities in the USA, Europe, and India, depending on whether it is the innovator or a generic version.

Related Products

Efavirenz

Strength:
Tab: 200 mg, 600 mg; Cap: 50 mg, 100 mg, 200 mg

Form: Tablet & Capsule

Reference Brands: Sustiva®(US); Stocrin®(EU)

View Details
Lamivudine & Zidovudine

Strength:
Lamivudine 150 mg + Zidovudine 300 mg

Form: Tablet

Reference Brands: Combivir®(US/ EU)

View Details
Atazanavir & Ritonavir

Strength:
300 mg Atazanavir + 100 mg Ritonavir

Form: Tablets

Reference Brands: Evotaz®(US)

View Details
Abacavir Sulphate

Strength:
Tab: 300 mg; oral solution: 20 mg/ml

Form: Tablet and Oral Solution

Reference Brands: Ziagen® (EU & US)

View Details
Valganciclovir

Strength:
Tab: 450 mg; Oral solution: 50 mg/mL

Form: Tablet & Oral solution

Reference Brands: Valcyte®

View Details
Nelfinavir Mesylate

Strength:
Tablets: 250 mg, 625 mg: Oral Powder: 50 mg/g

Form: Tablet & Oral Powder

Reference Brands: Viracept®

View Details
Ritonavir & Lopinavir

Strength:
Tab: Lopinavir 200 mg + Ritonavir 50 mg; oral solution:80 mg / 20 mg per mL

Form: Tablet and Oral Solution

Reference Brands: Kaletra(US & EU)

View Details
Sofosbuvir / Ledipasvir

Strength:
Sofosbuvir 400 mg & Ledipasvir 90 mg

Form: Tablet

Reference Brands: Harvoni®(EU & US)

View Details
Enquire Now

Usually answered within 48 hours | GMP documents shared before you commit

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us